No Data
Express News | Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Express News | Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients With Non-CNS Met Fusion Solid Tumors From Its Phase 2 Sparta Trial
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
Express News | Apollomics - Sanjeev Redkar Co-Founder & President, Peony Yu, Chief Medical Officer to Transition to Consulting Roles
Express News | Apollomics Inc - Expects Over 50% Reduction in Ongoing Expenses
Express News | Apollomics Inc - Capital to Fund Operations Into Q3 2025